{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T21:42:50Z","timestamp":1774906970267,"version":"3.50.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T00:00:00Z","timestamp":1573603200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T00:00:00Z","timestamp":1573603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s42000-019-00147-z","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T11:04:22Z","timestamp":1573643062000},"page":"135-143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Glucose metabolism disorders in patients with adrenal gland disorders: pathophysiology and management"],"prefix":"10.1007","volume":"19","author":[{"given":"Kalliopi J.","family":"Ioakim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy I.","family":"Sydney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0651-1376","authenticated-orcid":false,"given":"Stavroula A.","family":"Paschou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,13]]},"reference":[{"key":"147_CR1","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.tem.2011.09.001","volume":"22","author":"G Mazziotti","year":"2011","unstructured":"Mazziotti G, Gazzaruso C, Giustina A (2011) Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol Metab 22:499\u2013506. https:\/\/doi.org\/10.1016\/j.tem.2011.09.001","journal-title":"Trends Endocrinol Metab"},{"key":"147_CR2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1742-7843.2011.00699.x","volume":"108","author":"V Fagerholm","year":"2011","unstructured":"Fagerholm V, Haaparanta M, Scheinin M (2011) \u0391 2-adrenoceptor regulation of blood glucose homeostasis. Basic Clin Pharmacol Toxicol 108:365\u2013370. https:\/\/doi.org\/10.1111\/j.1742-7843.2011.00699.x","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"147_CR3","doi-asserted-by":"publisher","first-page":"33873","DOI":"10.1074\/jbc.M504119200","volume":"280","author":"H Cassuto","year":"2005","unstructured":"Cassuto H, Kochan K, Chakravarty K et al (2005) Glucocorticoids regulate transcription of the gene for phosphoenolpyruvate carboxykinase in the liver via an extended glucocorticoid regulatory unit. J Biol Chem 280:33873\u201333884. https:\/\/doi.org\/10.1074\/jbc.M504119200","journal-title":"J Biol Chem"},{"key":"147_CR4","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/nri1937","volume":"6","author":"H Tilg","year":"2006","unstructured":"Tilg H, Moschen AR (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6:772\u2013783. https:\/\/doi.org\/10.1038\/nri1937","journal-title":"Nat Rev Immunol"},{"key":"147_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ecl.2013.10.005","volume":"43","author":"EB Geer","year":"2014","unstructured":"Geer EB, Islam J, Buettner C (2014) Mechanisms of glucocorticoid-induced insulin resistance. Endocrinol Metab Clin N Am 43:75\u2013102. https:\/\/doi.org\/10.1016\/j.ecl.2013.10.005","journal-title":"Endocrinol Metab Clin N Am"},{"key":"147_CR6","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1210\/endo-126-5-2635","volume":"126","author":"B Fischer","year":"1990","unstructured":"Fischer B, Rausch U, Wollny P, Westphal H, Seitz JAG (1990) Immunohistochemical localization of the glucocorticoid receptor pancreatic beta-cells of the rat. Endocrinology 126:2635\u20132641","journal-title":"Endocrinology"},{"key":"147_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0166077","volume":"11","author":"A Kamba","year":"2016","unstructured":"Kamba A, Daimon M, Murakami H et al (2016) Association between higher serum cortisol levels and decreased insulin secretion in a general population. PLoS One 11:1\u201310. https:\/\/doi.org\/10.1371\/journal.pone.0166077","journal-title":"PLoS One"},{"key":"147_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0167-0115(03)00111-3","volume":"114","author":"T Vilsb\u00f8ll","year":"2003","unstructured":"Vilsb\u00f8ll T, Krarup T, Madsbad S, Holst JJ (2003) Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 114:115\u2013121. https:\/\/doi.org\/10.1016\/S0167-0115(03)00111-3","journal-title":"Regul Pept"},{"key":"147_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/BF02427280","volume":"29","author":"M Nauck","year":"1986","unstructured":"Nauck M, St\u00f6ckmann F, Ebert RCW (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46\u201352","journal-title":"Diabetologia"},{"key":"147_CR10","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1210\/jc.2010-0119","volume":"95","author":"KB Hansen","year":"2010","unstructured":"Hansen KB, Vilsb\u00f8ll T, Bagger JI et al (2010) Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. J Clin Endocrinol Metab 95:3309\u20133317. https:\/\/doi.org\/10.1210\/jc.2010-0119","journal-title":"J Clin Endocrinol Metab"},{"key":"147_CR11","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1210\/jc.2009-2453","volume":"95","author":"K Mullan","year":"2010","unstructured":"Mullan K, Black N, Thiraviaraj A et al (2010) Is there value in routine screening for Cushing\u2019s syndrome in patients with diabetes? J Clin Endocrinol Metab 95:2262\u20132265. https:\/\/doi.org\/10.1210\/jc.2009-2453","journal-title":"J Clin Endocrinol Metab"},{"key":"147_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1530\/EJE-11-1095","volume":"167","author":"RA Feelders","year":"2012","unstructured":"Feelders RA, Pulgar SJ, Kempel A, Pereira AM (2012) The burden of Cushing\u2019s disease: clinical and health-related quality of life aspects. Eur J Endocrinol 167:311\u2013326. https:\/\/doi.org\/10.1530\/EJE-11-1095","journal-title":"Eur J Endocrinol"},{"key":"147_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1210\/er.2000-0001","volume":"24","author":"LJ Hofland","year":"2003","unstructured":"Hofland LJ, Lamberts SWJ (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24:28\u201347. https:\/\/doi.org\/10.1210\/er.2000-0001","journal-title":"Endocr Rev"},{"key":"147_CR14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1210\/er.2016-1105","volume":"38","author":"C Scaroni","year":"2017","unstructured":"Scaroni C, Zilio M, Foti M, Boscaro M (2017) Glucose metabolism abnormalities in cushing syndrome: from molecular basis to clinical management. Endocr Rev 38:189\u2013219. https:\/\/doi.org\/10.1210\/er.2016-1105","journal-title":"Endocr Rev"},{"key":"147_CR15","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J et al (2012) A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med 366:914\u2013924. https:\/\/doi.org\/10.1056\/NEJMoa1105743","journal-title":"N Engl J Med"},{"key":"147_CR16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11102-013-0539-4","volume":"17","author":"J MacKenzie Feder","year":"2014","unstructured":"MacKenzie Feder J, Bourdeau I, Vallette S et al (2014) Pasireotide monotherapy in Cushing\u2019s disease: a single-centre experience with 5-year extension of phase III trial. Pituitary 17:519\u2013529. https:\/\/doi.org\/10.1007\/s11102-013-0539-4","journal-title":"Pituitary"},{"key":"147_CR17","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s11102-013-0503-3","volume":"17","author":"M Boscaro","year":"2014","unstructured":"Boscaro M, Bertherat J, Findling J et al (2014) Extended treatment of Cushing\u2019s disease with pasireotide: results from a 2-year, phase II study. Pituitary 17:320\u2013326. https:\/\/doi.org\/10.1007\/s11102-013-0503-3","journal-title":"Pituitary"},{"key":"147_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.diabet.2012.10.005","volume":"39","author":"Y Reznik","year":"2013","unstructured":"Reznik Y, Bertherat J, Borson-Chazot F et al (2013) Management of hyperglycaemia in Cushing\u2019s disease: experts\u2019 proposals on the use of pasireotide. Diabetes Metab 39:34\u201341. https:\/\/doi.org\/10.1016\/j.diabet.2012.10.005","journal-title":"Diabetes Metab"},{"key":"147_CR19","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2337\/dc12-0413","volume":"35","author":"SE Inzucchi","year":"2012","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care 35:1364\u20131379. https:\/\/doi.org\/10.2337\/dc12-0413","journal-title":"Diabetes Care"},{"key":"147_CR20","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s11102-016-0734-1","volume":"19","author":"JM Silverstein","year":"2016","unstructured":"Silverstein JM (2016) Hyperglycemia induced by pasireotide in patients with Cushing\u2019s disease or acromegaly. Pituitary 19:536\u2013543. https:\/\/doi.org\/10.1007\/s11102-016-0734-1","journal-title":"Pituitary"},{"key":"147_CR21","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s00268-005-0681-x","volume":"30","author":"Y Erbil","year":"2006","unstructured":"Erbil Y, Ademo\u01e7lu E, \u00d6zbey N et al (2006) Evaluation of the cardiovascular risk in patients with subclinical Cushing syndrome before and after surgery. World J Surg 30:1665\u20131671. https:\/\/doi.org\/10.1007\/s00268-005-0681-x","journal-title":"World J Surg"},{"key":"147_CR22","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1210\/jc.2002-020399","volume":"87","author":"I Chiodini","year":"2002","unstructured":"Chiodini I, Tauchmanov\u00e0 L, Torlontano M et al (2002) Bone involvement in eugonadal male patients with adrenal incidentaloma and subclinical hypercortisolism. J Clin Endocrinol Metab 87:5491\u20135494. https:\/\/doi.org\/10.1210\/jc.2002-020399","journal-title":"J Clin Endocrinol Metab"},{"key":"147_CR23","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.1210\/jc.2001-011766","volume":"87","author":"L Tauchmanov\u00e0","year":"2002","unstructured":"Tauchmanov\u00e0 L, Rossi R, Biondi B et al (2002) Patients with subclinical Cushing\u2019s syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 87:4872\u20134878. https:\/\/doi.org\/10.1210\/jc.2001-011766","journal-title":"J Clin Endocrinol Metab"},{"key":"147_CR24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1530\/EJE-09-1034","volume":"162","author":"DH Van Raalte","year":"2010","unstructured":"Van Raalte DH, Nofrate V, Bunck MC et al (2010) Acute and 2-week exposure to prednisolone impair different aspects of \u03b2-cell function in healthy men. Eur J Endocrinol 162:729\u2013735. https:\/\/doi.org\/10.1530\/EJE-09-1034","journal-title":"Eur J Endocrinol"},{"key":"147_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1530\/eje.0.149027365","volume":"149","author":"L Barzon","year":"2003","unstructured":"Barzon L, Sonino N, Fallo F, Palu GBM (2003) Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 149:273\u2013285. https:\/\/doi.org\/10.1530\/eje.0.149027365","journal-title":"Eur J Endocrinol"},{"key":"147_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s12020-015-0776-6","volume":"51","author":"SA Paschou","year":"2016","unstructured":"Paschou SA, Kandaraki E, Dimitropoulou F et al (2016) Subclinical Cushing\u2019s syndrome in patients with bilateral compared to unilateral adrenal incidentalomas: a systematic review and meta-analysis. Endocrine 51:225\u2013235. https:\/\/doi.org\/10.1007\/s12020-015-0776-6","journal-title":"Endocrine"},{"key":"147_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1046\/j.1365-2265.1998.00437.x","volume":"49","author":"JM Fernandez-Real","year":"1998","unstructured":"Fernandez-Real JM, Ricart EW, Sim\u00f2 R, Salinas IWS (1998) Study of glucose tolerance in consecutive patients harbouring incidental adrenal tumours. Clin Endocrinol 49:53\u201361","journal-title":"Clin Endocrinol"},{"key":"147_CR28","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/ijc.29950","volume":"138","author":"B Altieri","year":"2016","unstructured":"Altieri B, Tirabassi G, Della CS et al (2016) Adrenocortical tumors and insulin resistance: what is the first step? Int J Cancer 138:2785\u20132794. https:\/\/doi.org\/10.1002\/ijc.29950","journal-title":"Int J Cancer"},{"key":"147_CR29","first-page":"755","volume":"8","author":"K Shimamoto","year":"1994","unstructured":"Shimamoto K, Shiiki M, Ise T et al (1994) Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism? J Hypertens 8:755\u2013759","journal-title":"J Hypertens"},{"key":"147_CR30","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.steroids.2014.08.016","volume":"91","author":"JM Luther","year":"2014","unstructured":"Luther JM (2014) Effects of aldosterone on insulin sensitivity and secretion. Steroids 91:54\u201360. https:\/\/doi.org\/10.1016\/j.steroids.2014.08.016","journal-title":"Steroids"},{"key":"147_CR31","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/10641963.2016.1182176","volume":"38","author":"D Watanabe","year":"2016","unstructured":"Watanabe D, Yatabe M, Ichihara A (2016) Evaluation of insulin sensitivity and secretion in primary aldosteronism. Clin Exp Hypertens 38:613\u2013617. https:\/\/doi.org\/10.1080\/10641963.2016.1182176","journal-title":"Clin Exp Hypertens"},{"key":"147_CR32","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1161\/hypertensionaha.111.180521","volume":"58","author":"E Kumagai","year":"2011","unstructured":"Kumagai E, Adachi H, Jacobs DR et al (2011) Plasma aldosterone levels and development of insulin resistance. Hypertension 58:1043\u20131048. https:\/\/doi.org\/10.1161\/hypertensionaha.111.180521","journal-title":"Hypertension"},{"key":"147_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/cen.13370","volume":"87","author":"M Tancredi","year":"2017","unstructured":"Tancredi M, Johannsson G, Eliasson B et al (2017) Prevalence of primary aldosteronism among patients with type 2 diabetes. Clin Endocrinol 87:233\u2013241. https:\/\/doi.org\/10.1111\/cen.13370","journal-title":"Clin Endocrinol"},{"key":"147_CR34","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1365-2265.2007.02775.x","volume":"66","author":"WF Young","year":"2007","unstructured":"Young WF (2007) Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol 66:607\u2013618. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02775.x","journal-title":"Clin Endocrinol"},{"key":"147_CR35","doi-asserted-by":"publisher","first-page":"S508","DOI":"10.1097\/01.CCM.0000278047.06965.20","volume":"35","author":"E Barth","year":"2007","unstructured":"Barth E, Albuszies G, Baumgart K et al (2007) Glucose metabolism and catecholamines. Crit Care Med 35:S508\u2013S518. https:\/\/doi.org\/10.1097\/01.CCM.0000278047.06965.20","journal-title":"Crit Care Med"},{"key":"147_CR36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jdiacomp.2007.02.006","volume":"22","author":"S Douma","year":"2008","unstructured":"Douma S, Petidis K, Kartali N et al (2008) Pheochromocytoma presenting as diabetic ketoacidosis. J Diabetes Complicat 22:295\u2013296. https:\/\/doi.org\/10.1016\/j.jdiacomp.2007.02.006","journal-title":"J Diabetes Complicat"},{"key":"147_CR37","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1245\/s10434-016-5701-6","volume":"24","author":"T Beninato","year":"2017","unstructured":"Beninato T, Kluijfhout WP, Drake FT et al (2017) Resection of pheochromocytoma improves diabetes mellitus in the majority of patients. Ann Surg Oncol 24:1208\u20131213. https:\/\/doi.org\/10.1245\/s10434-016-5701-6","journal-title":"Ann Surg Oncol"},{"key":"147_CR38","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.2337\/diacare.23.10.1591","volume":"23","author":"M Bluher","year":"2000","unstructured":"Bluher M, Windgassen MPR (2000) Improvement of insulin sensitivity after adrenalectomy in patients with pheochromocytoma. Diabetes Care 23:1591\u20131592","journal-title":"Diabetes Care"},{"key":"147_CR39","doi-asserted-by":"publisher","first-page":"999","DOI":"10.4158\/ep171914.ra","volume":"23","author":"B Mesmar","year":"2017","unstructured":"Mesmar B, Poola-Kella S, Malek R (2017) The physiology behind diabetes mellitus in patients with pheochromocytoma: a review of the literature. Endocr Pract 23:999\u20131005. https:\/\/doi.org\/10.4158\/ep171914.ra","journal-title":"Endocr Pract"},{"key":"147_CR40","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1097\/00004872-200309000-00020","volume":"21","author":"A La Batide-Alanore","year":"2003","unstructured":"La Batide-Alanore A, Chatellier GPP-F (2003) Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertens 21:1703\u20131707","journal-title":"J Hypertens"},{"key":"147_CR41","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S0002-9610(85)80186-0","volume":"149","author":"M Abecassis","year":"1985","unstructured":"Abecassis M, McLoughlin MJ, Langer B, Kudlow JE (1985) Serendipitous adrenal masses: prevalence, significance, and management. Am J Surg 149:783\u2013788","journal-title":"Am J Surg"},{"key":"147_CR42","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/BF03344099","volume":"29","author":"S Bovio","year":"2006","unstructured":"Bovio S, Cataldi A, Reimondo G et al (2006) Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Investig 29:298\u2013302","journal-title":"J Endocrinol Investig"},{"key":"147_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.maturitas.2018.12.002","volume":"121","author":"GI Sydney","year":"2019","unstructured":"Sydney GI, Ioakim KJ, Paschou SA (2019) Insulin resistance and adrenal incidentalomas: a bidirectional relationship. Maturitas 121:1\u20136. https:\/\/doi.org\/10.1016\/j.maturitas.2018.12.002","journal-title":"Maturitas"},{"key":"147_CR44","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.metabol.2012.12.006","volume":"62","author":"M Ivovic","year":"2013","unstructured":"Ivovic M, Marina LV, Vujovic S et al (2013) Nondiabetic patients with either subclinical Cushing\u2019s or nonfunctional adrenal incidentalomas have lower insulin sensitivity than healthy controls: clinical implications. Metabolism 62:786\u2013792. https:\/\/doi.org\/10.1016\/j.metabol.2012.12.006","journal-title":"Metabolism"},{"key":"147_CR45","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/07435809609043773","volume":"22","author":"M Reincke","year":"1997","unstructured":"Reincke M, Fassnacht M, V\u00e4th S, Mora PAB (1997) Adrenal incidentalomas: a manifestation of the metabolic syndrome? Endocr Res 22:757\u2013761","journal-title":"Endocr Res"},{"key":"147_CR46","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1365-2265.2010.03928.x","volume":"74","author":"G Muscogiuri","year":"2011","unstructured":"Muscogiuri G, Sorice GP, Prioletta A, Mezza T, Cipolla C, Salomone E, Giaccari A, Pontecorvi ADCS (2011) The size of adrenal incidentalomas correlates with insulin resistance. Is there a cause-effect relationship? Clin Endocrinol 74:300\u2013305","journal-title":"Clin Endocrinol"},{"key":"147_CR47","doi-asserted-by":"publisher","first-page":"521","DOI":"10.4149\/neo","volume":"56","author":"H Wagnerova","year":"2009","unstructured":"Wagnerova H, Dudasova DLI (2009) Hormonal and metabolic evaluation of adrenal incidentalomas. Neoplasma 56:521\u2013525. https:\/\/doi.org\/10.4149\/neo","journal-title":"Neoplasma"},{"key":"147_CR48","first-page":"627","volume-title":"Textbook of Endocrinology","author":"J Ensincks","year":"1974","unstructured":"Ensincks J, Williams RH (1974) Disorders causing hypoglycemia. In: Williams RH (ed) Textbook of Endocrinology, 5th edn. Saunders, Philadelphia, pp 627\u2013659","edition":"5"},{"key":"147_CR49","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1620\/tjem.132.49","volume":"132","author":"KWH Yoshikawa","year":"1980","unstructured":"Yoshikawa KWH (1980) Hypoglycemia by adrenocortical carcinoma with Cushing\u2019s syndrome. Tohoku J Exp Med 132:49\u201360","journal-title":"Tohoku J Exp Med"},{"key":"147_CR50","first-page":"482","volume":"79","author":"CL Aszkanazy","year":"1958","unstructured":"Aszkanazy CL, Jenkins LSW (1958) Adrenal cortical carcinoma associated with hypoglycemia. Canad M A J 79:482\u2013484","journal-title":"Canad M A J"},{"key":"147_CR51","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1159\/000486004","volume":"49","author":"GAHE Ueland","year":"2018","unstructured":"Ueland GAHE (2018) Metabolic complications in adrenal insufficiency. Front Horm Res 49:104\u2013113. https:\/\/doi.org\/10.1159\/000486004","journal-title":"Front Horm Res"},{"key":"147_CR52","doi-asserted-by":"publisher","unstructured":"Mazziotti G, Formenti AM, Frara S et al (2017) Diabetes in Cushing disease. Curr Diab Rep 17. https:\/\/doi.org\/10.1007\/s11892-017-0860-9","DOI":"10.1007\/s11892-017-0860-9"},{"key":"147_CR53","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.maturitas.2016.07.017","volume":"92","author":"SA Paschou","year":"2016","unstructured":"Paschou SA, Vryonidou A, Goulis DG (2016) Adrenal incidentalomas: a guide to assessment , treatment and follow-up. Maturitas 92:79\u201385. https:\/\/doi.org\/10.1016\/j.maturitas.2016.07.017","journal-title":"Maturitas"},{"issue":"Suppl 1","key":"147_CR54","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1159\/000314316","volume":"92","author":"AN-PJ Munir","year":"2010","unstructured":"Munir AN-PJ (2010) Management of diabetes mellitus in Cushing\u2019s syndrome. Neuroendocrinology 92(Suppl 1):82\u201385","journal-title":"Neuroendocrinology"},{"key":"147_CR55","doi-asserted-by":"publisher","first-page":"M133","DOI":"10.1530\/EJE-15-0354","volume":"173","author":"FKM Ferra\u00f9","year":"2015","unstructured":"Ferra\u00f9 FKM (2015) Metabolic comorbidities in Cushing\u2019s syndrome. Eur J Endocrinol 173:M133\u2013M157. https:\/\/doi.org\/10.1530\/EJE-15-0354","journal-title":"Eur J Endocrinol"},{"key":"147_CR56","doi-asserted-by":"publisher","unstructured":"Poli G, Cantini G, Armignacco R, Fucci R, Santi R, Canu L, Nesi G, Mannelli MLM (2016) Metformin as a new anti-cancer drug in adrenocortical carcinoma. Oncotarget. https:\/\/doi.org\/10.18632\/oncotarget.10421","DOI":"10.18632\/oncotarget.10421"},{"key":"147_CR57","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.mce.2014.07.007","volume":"394","author":"Z Pan","year":"2014","unstructured":"Pan Z, Xie D, Choudhary V et al (2014) The effect of pioglitazone on aldosterone and cortisol production in HAC15 human adrenocortical carcinoma cells. Mol Cell Endocrinol 394:119\u2013128. https:\/\/doi.org\/10.1016\/j.mce.2014.07.007","journal-title":"Mol Cell Endocrinol"},{"key":"147_CR58","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1530\/eje.0.1510173","volume":"151","author":"B Ambrosi","year":"2004","unstructured":"Ambrosi B, Arosio M, Dall\u2019Asta C, Cannavo S, Libe R, Vigo T, Chiodini I, Epaminonda P, Trimarchi FB-PP (2004) Effects of the chronic administration of the PPAR\u03b3 receptor ligand, rosiglitazone, in Cushing\u2019s disease. Eur J Endocrinol 151:173\u2013178","journal-title":"Eur J Endocrinol"},{"key":"147_CR59","unstructured":"Alevizaki M, Philippou G, Zapanti L, Alevizaki CC, Anastasiou E MM (2004) Significant improvement of recurrent pituitary-dependent Cushing\u2019s syndrome after administration of a PPAR\u03b3 agonist. Progr 86th Annu Meet Endocr Soc New Orleans, LA 418 (Abstract P2-453)"},{"key":"147_CR60","doi-asserted-by":"publisher","first-page":"RC8","DOI":"10.1007\/BF03345281","volume":"27","author":"S Cannavo","year":"2004","unstructured":"Cannavo S, Ambrosi B, Chiodini I, Vigo T, Russo A, Milici C, Barbetta L, Dall\u2019Asta C, Adda GAM (2004) Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor-\u03b3 ligand, rosiglitazone, in Cushing\u2019s disease. J Endocrinol Investig 27:RC8\u2013RC11","journal-title":"J Endocrinol Investig"},{"key":"147_CR61","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1210\/jc.2004-1746","volume":"90","author":"D Suri","year":"2005","unstructured":"Suri D, Weiss RE (2005) Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing\u2019s disease. J Clin Endocrinol Metab 90:1340\u20131346","journal-title":"J Clin Endocrinol Metab"},{"key":"147_CR62","doi-asserted-by":"publisher","first-page":"469","DOI":"10.4158\/EP08331.RAR","volume":"15","author":"JNT-HL Clore","year":"2009","unstructured":"Clore JNT-HL (2009) Glucocorticoid-induced hyperglycemia. Endocr Pr 15:469\u2013474","journal-title":"Endocr Pr"},{"key":"147_CR63","doi-asserted-by":"publisher","first-page":"412","DOI":"10.2337\/dc10-1677","volume":"34","author":"DH van Raalte","year":"2011","unstructured":"van Raalte DH et al (2011) Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care 34:412\u2013417","journal-title":"Diabetes Care"},{"key":"147_CR64","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s40265-013-0112-5","volume":"73","author":"AWB Anderson","year":"2013","unstructured":"Anderson AWB (2013) 11b-HSD1 inhibitors for the treatment of type 2 diabetes and cardiovascular disease. Drugs 73:1385\u20131393","journal-title":"Drugs"},{"key":"147_CR65","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.cell.2007.05.047","volume":"130","author":"NK Lee","year":"2007","unstructured":"Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JDC, Dacquin R, Mee PJ, McKee MD, Jung DYZZ, Kim JK, Mauvais-Jarvis F, Ducy PKG (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130:456\u2013469","journal-title":"Cell"},{"key":"147_CR66","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10928-016-9475-z","volume":"43","author":"DJ Conrado","year":"2016","unstructured":"Conrado DJ, Krishnaswami S, Shoji S, Kolluri SH-HJ, McCabe D, Rojo RTB (2016) Predicting the probability of successful efficacy of a dissociated agonist of the glucocorticoid receptor from dose-response analysis. J Pharmacokinet Pharmacodyn 43:325\u2013341","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"147_CR67","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cca.2008.07.001","volume":"396","author":"J Im","year":"2008","unstructured":"Im J, Yu B, Jeon J, Kim S (2008) Relationship between osteocalcin and glucose metabolism in postmenopausal women. Clin Chim Acta 396:66\u201369","journal-title":"Clin Chim Acta"},{"key":"147_CR68","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/dmrr.1045","volume":"25","author":"Y Hwang","year":"2009","unstructured":"Hwang Y, Jeong I, Ahn K, Chung H (2009) The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced beta-cell function in middle-aged male subjects. Diabetes Metab Res Rev 25:768\u2013772","journal-title":"Diabetes Metab Res Rev"},{"key":"147_CR69","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2337\/dc09-1237","volume":"33","author":"Y Winhofer","year":"2010","unstructured":"Winhofer Y, Handisurya A, Tura A et al (2010) Osteocalcin is related to enhanced insulin secretion in gestational diabetes. Diabetes Care 33:139\u2013143","journal-title":"Diabetes Care"},{"key":"147_CR70","doi-asserted-by":"crossref","unstructured":"Fischer E, Adolf C, Pallauf A, Then C, Bidlingmaier M, Beuschlein F, Seissler JRM (2013) Aldosterone excess impairs first phase insulin secretion in primary aldosteronism. J Clin Endocrinol Metab 98:2513\u20132520","DOI":"10.1210\/jc.2012-3934"},{"key":"147_CR71","doi-asserted-by":"publisher","first-page":"334","DOI":"10.5603\/EP.2017.0026","volume":"68","author":"A Rogowicz-Frontczak","year":"2017","unstructured":"Rogowicz-Frontczak A, Majchrzak A, Zozuli\u0144ska-Zi\u00f3\u0142kiewicz D (2017) Insulin resistance in endocrine disorders \u2014 treatment options. Endokrynol Pol 68:334\u2013342. https:\/\/doi.org\/10.5603\/EP.2017.0026","journal-title":"Endokrynol Pol"},{"key":"147_CR72","doi-asserted-by":"publisher","first-page":"R135","DOI":"10.1530\/EC-18-0109","volume":"7","author":"E Kardalas","year":"2018","unstructured":"Kardalas E, Paschou SA, Anagnostis P et al (2018) Hypokalemia: a clinical update. Endocr Connect 7:R135\u2013R146","journal-title":"Endocr Connect"},{"key":"147_CR73","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1210\/jc.2006-0736","volume":"91","author":"C Catena","year":"2006","unstructured":"Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, Favret G, Melis ACA, Sechi LA (2006) Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 91:3457\u20133463","journal-title":"J Clin Endocrinol Metab"},{"key":"147_CR74","doi-asserted-by":"publisher","first-page":"61","DOI":"10.14310\/horm.2002.1184","volume":"2","author":"E Diamanti-Kandarakis","year":"2003","unstructured":"Diamanti-Kandarakis E, Zapanti E, Peridis MH et al (2003) Insulin resistance in pheochromocytoma improves more by surgical rather than by medical treatment. Horm (Athens) 2:61\u201366","journal-title":"Horm (Athens)"},{"key":"147_CR75","doi-asserted-by":"crossref","unstructured":"Pogorzelski R, Toutounchi S, Krajewska E et al (2014) The effect of surgical treatment of phaeochromocytoma on concomitant arterial hypertension and diabetes mellitus in a single-centre retrospective study. Cent Eur J Urol 67:361\u2013365","DOI":"10.5173\/ceju.2014.04.art9"},{"key":"147_CR76","doi-asserted-by":"crossref","unstructured":"Stenstrom G, Sjostrom LSU (1984) Diabetes mellitus in phaeochromocytoma: fasting blood glucose levels before and after surgery in 60 patients with phaeochromocytoma. Acta Endocrinol 106:511\u2013515","DOI":"10.1530\/acta.0.1060511"},{"key":"147_CR77","doi-asserted-by":"publisher","unstructured":"Bornstein SR, Allolio B, Arlt Wet al (2015) Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 101:364\u2013389. https:\/\/doi.org\/10.1210\/jc.2015-1710","DOI":"10.1210\/jc.2015-1710"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-019-00147-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s42000-019-00147-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-019-00147-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:15:26Z","timestamp":1605140126000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s42000-019-00147-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,13]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["147"],"URL":"https:\/\/doi.org\/10.1007\/s42000-019-00147-z","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,13]]},"assertion":[{"value":"11 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}